Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Instagram Outage Disrupts Thousands of U.S. Users 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
LIVONIA, Mich., June 01, 2017 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced that management will provide a corporate update at LD Micro Invitational, taking place June 6-7 in Los Angeles, California, and at the Jefferies 2017 Global Healthcare Conference, taking place June 6-9, 2017, in New York City.
| LD Micro Invitational | |||
| Date: | Tuesday, June 6th | ||
| Time: | 4:00 pm Pacific Time | ||
| Presenter: | Charles Bisgaier, Ph.D., Chief Scientific Officer | ||
| Location: | Luxe Sunset Boulevard Hotel, Los Angeles, CA | ||
| Jefferies 2017 Global Healthcare Conference | |||
| Date: | Thursday, June 8th | ||
| Time: | 4:00pm Eastern Time | ||
| Presenter: | Lee Golden, MD, Chief Medical Officer | ||
| Location: | Grand Hyatt Hotel, Imperial Ballroom | ||
| Webcast: | http://wsw.com/webcast/jeff105/gemp | ||
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemphire has 3 clinical trials ongoing for homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic cardiovascular disease (ASCVD), and severe hypertriglyceridemia (SHTG) under NCT02722408, NCT02634151, and NCT02944383, respectively with a fourth planned trial in NASH in second half of 2017. Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734)-245-1700
